1 (800) 227-9902
- Lowest crossing profile
- Greatest maximum expansion in small diameter sizes
- Up to 5.5 mm expansion to treat large vessels
- Better pushability and flexibility in complex anatomy
- Best-in-class safety & efficacy profile
Abbott Vascular has received FDA approval for the XIENCE Sierra drug-eluting stent (DES). The device introduces Slim Flex Technology, allowing the stent to be crimped tighter and resulting in the lowest crossing profile on the market. Delivery system innovations improve the device’s pushability and flexibility in challenging anatomy, while a new implant design allows XIENCE Sierra to reach 5.5 mm expansion in the 3.5 and 4.0 mm diameter sizes for the treatment of large vessels. XIENCE Sierra also maintains the best-in-class safety and efficacy profile of the XIENCE family of DES.
“We developed XIENCE Sierra so that physicians can more easily deliver the stent even in challenging cases,” said Chuck Brynelsen, Senior Vice President of Abbott’s vascular business. “The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”
The XIENCE Sierra DES is available for use in the European Union, Japan, and the United States.